메뉴 건너뛰기




Volumn 29, Issue 15, 2011, Pages 2104-2120

Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; SRL 172; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

EID: 79957520182     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.3683     Document Type: Review
Times cited : (89)

References (87)
  • 2
    • 25644461068 scopus 로고    scopus 로고
    • International lung cancer trends by histologic type: Male:female differences diminishing and adenocarcinoma rates rising
    • DOI 10.1002/ijc.21183
    • Devesa SS, Bray F, Vizcaino AP, et al: International lung cancer trends by histologic type: Male: female differences diminishing and adenocarcinoma rising. Int J Cancer 117:294-299, 2005 (Pubitemid 41379403)
    • (2005) International Journal of Cancer , vol.117 , Issue.2 , pp. 294-299
    • Devesa, S.S.1    Bray, F.2    Vizcaino, A.P.3    Parkin, D.M.4
  • 3
    • 45349096041 scopus 로고    scopus 로고
    • American Cancer Society. Atlanta, GA, American Cancer Society
    • American Cancer Society: Cancer Facts and Figures 2008. Atlanta, GA, American Cancer Society, 2008
    • (2008) Cancer Facts and Figures 2008
  • 4
    • 77950520452 scopus 로고    scopus 로고
    • Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two metaanalyses of individual patient data
    • NSCLC Meta-analyses Collaborative Group
    • NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al: Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two metaanalyses of individual patient data. Lancet 375:1267-1277, 2010
    • (2010) Lancet , vol.375 , pp. 1267-1277
    • Arriagada, R.1    Auperin, A.2
  • 5
    • 75749145931 scopus 로고    scopus 로고
    • Management of patients with advanced non-small cell lung cancer: Current and emerging options
    • Triano LR, Deshpande H, Gettinger SN: Management of patients with advanced non-small cell lung cancer: Current and emerging options. Drugs 70:167-179, 2010
    • (2010) Drugs , vol.70 , pp. 167-179
    • Triano, L.R.1    Deshpande, H.2    Gettinger, S.N.3
  • 6
    • 62549108221 scopus 로고    scopus 로고
    • Toxicity of targeted therapy in non-small-cell lung cancer management
    • Ricciardi S, Tomao S, de Marinis F: Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28-35, 2009
    • (2009) Clin Lung Cancer , vol.10 , pp. 28-35
    • Ricciardi, S.1    Tomao, S.2    De Marinis, F.3
  • 7
    • 36048995250 scopus 로고    scopus 로고
    • Patientreported outcomes to support medical product labeling claims: FDA perspective
    • Patrick DL, Burke LB, Powers JH, et al: Patientreported outcomes to support medical product labeling claims: FDA perspective. Value Health 2:215-237, 2007
    • (2007) Value Health , vol.2 , pp. 215-237
    • Patrick, D.L.1    Burke, L.B.2    Powers, J.H.3
  • 8
    • 0142121284 scopus 로고    scopus 로고
    • Beyond the development of health-related quality-of-life (HRQOL) measures: A checklist for evaluating HRQOL outcomes in cancer clinical trials - Does HRQOL evaluation in prostate cancer research inform clinical decision making?
    • DOI 10.1200/JCO.2003.12.121
    • Efficace F, Bottomley A, Osoba D, et al: Beyond the development of health-related quality of life (HRQOL) measures: A checklist for evaluation of HRQOL outcomes in cancer clinical trials-Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol 21:3502-3511, 2003 (Pubitemid 46594084)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.18 , pp. 3502-3511
    • Efficace, F.1    Bottomley, A.2    Osoba, D.3    Gotay, C.4    Flechtner, H.5    D'Haese, S.6    Zurlo, A.7
  • 9
    • 0347285244 scopus 로고    scopus 로고
    • Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials
    • DOI 10.1016/j.ejca.2003.10.012
    • Efficace F, Bottomley A, Vanvoorden V, et al: Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials. Eur J Cancer 40:187-197, 2004 (Pubitemid 38077020)
    • (2004) European Journal of Cancer , vol.40 , Issue.2 , pp. 187-197
    • Efficace, F.1    Bottomley, A.2    Vanvoorden, V.3    Blazeby, J.M.4
  • 10
    • 34047138486 scopus 로고    scopus 로고
    • Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making
    • DOI 10.1093/annonc/mdl494
    • Efficace F, Osoba D, Gotay C, et al: Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Ann Oncol 18:775-781, 2007 (Pubitemid 46523284)
    • (2007) Annals of Oncology , vol.18 , Issue.4 , pp. 775-781
    • Efficace, F.1    Osoba, D.2    Gotay, C.3    Sprangers, M.4    Coens, C.5    Bottomley, A.6
  • 11
    • 77949449401 scopus 로고    scopus 로고
    • What changes in health-related quality of life matter to multiple myeloma patients? A prospective study
    • Kvam AK, Fayers P, Wisloff F: What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol 84:345-353, 2010
    • (2010) Eur J Haematol , vol.84 , pp. 345-353
    • Kvam, A.K.1    Fayers, P.2    Wisloff, F.3
  • 12
    • 77954321859 scopus 로고    scopus 로고
    • Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    • D'Addario G, Früh M, Reck M, et al: Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v116-v119, 2010 (suppl 5)
    • (2010) Ann Oncol , vol.21 , Issue.SUPPL. 5
    • D'addario, G.1    Früh, M.2    Reck, M.3
  • 13
    • 0042887522 scopus 로고    scopus 로고
    • Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials
    • DOI 10.1200/JCO.2003.01.203
    • Bottomley A, Efficace F, Thomas R, et al: Health-related quality of life in non-small-cell lung cancer: Methodologic issues in randomized controlled trials. J Clin Oncol 21:2982-2992, 2003 (Pubitemid 46621851)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.15 , pp. 2982-2992
    • Bottomley, A.1    Efficace, F.2    Thomas, R.3    Vanvoorden, V.4    Ahmedzai, S.H.5
  • 16
    • 0037206299 scopus 로고    scopus 로고
    • Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: Results of a randomized controlled trial
    • Falk SJ, Girling DJ, White RJ, et al: Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: Results of a randomized controlled trial. BMJ 325:465, 2002
    • (2002) BMJ , vol.325 , pp. 465
    • Falk, S.J.1    Girling, D.J.2    White, R.J.3
  • 23
    • 0346560025 scopus 로고    scopus 로고
    • Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975
    • DOI 10.1200/JCO.2003.03.195
    • Smit EF, van Meerbeeck JP, Lianes P, et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 21:3909-3917, 2003 (Pubitemid 46606203)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.21 , pp. 3909-3917
    • Smit, E.F.1    Van Meerbeeck, J.P.A.M.2    Lianes, P.3    Debruyne, C.4    Legrand, C.5    Schramel, F.6    Smit, H.7    Gaafar, R.8    Biesma, B.9    Manegold, C.10    Neymark, N.11    Giaccone, G.12
  • 31
    • 34248591512 scopus 로고    scopus 로고
    • Closeness to Death and Quality of Life in Advanced Lung Cancer Patients
    • DOI 10.1016/j.clon.2007.02.008, PII S0936655507005225
    • Brown S, Thorpe H, Napp V, et al: Closeness to death and quality of life in advanced lung cancer patients. Clin Oncol (R Coll Radiol) 19:341-348, 2007 (Pubitemid 46760596)
    • (2007) Clinical Oncology , vol.19 , Issue.5 , pp. 341-348
    • Brown, S.1    Thorpe, H.2    Napp, V.3    Brown, J.4
  • 32
    • 12344334587 scopus 로고    scopus 로고
    • Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer
    • DOI 10.1093/annonc/mdi009
    • Lilenbaum RC, Chen CS, Chidiac T, et al: Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97-101, 2005 (Pubitemid 40124485)
    • (2005) Annals of Oncology , vol.16 , Issue.1 , pp. 97-101
    • Lilenbaum, R.C.1    Chen, C.-S.2    Chidiac, T.3    Schwarzenberger, P.O.4    Thant, M.5    Versola, M.6    Lane, S.R.7
  • 34
    • 20244367173 scopus 로고    scopus 로고
    • Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status 70) and advanced non-small-cell lung cancer
    • DOI 10.1200/JCO.2005.01.003
    • Baka S, Ashcroft L, Anderson H, et al: Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small-cell lung cancer. J Clin Oncol 23:2136-2144, 2005 (Pubitemid 46218705)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.10 , pp. 2136-2144
    • Baka, S.1    Ashcroft, L.2    Anderson, H.3    Lind, M.4    Burt, P.5    Stout, R.6    Dowd, I.7    Smith, D.8    Lorigan, P.9    Thatcher, N.10
  • 36
    • 56349137675 scopus 로고    scopus 로고
    • Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: An analysis of RTOG 9801
    • Sarna L, Swann S, Langer C, et al: Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 72:1378-1384, 2008
    • (2008) Int J Radiat Oncol Biol Phys , vol.72 , pp. 1378-1384
    • Sarna, L.1    Swann, S.2    Langer, C.3
  • 37
    • 73349122621 scopus 로고    scopus 로고
    • Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801
    • Movsas B, Moughan J, Sarna L, et al: Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. J Clin Oncol 27:5816-5822, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 5816-5822
    • Movsas, B.1    Moughan, J.2    Sarna, L.3
  • 40
    • 20444364830 scopus 로고    scopus 로고
    • Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study
    • DOI 10.1016/j.radonc.2005.03.028, PII S0167814005001271
    • Sundstrøm S, Bremnes R, Brunsvig P, et al: Immediate or delayed radiotherapy in advanced nonsmall cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol 75: 141-148, 2005 (Pubitemid 40805242)
    • (2005) Radiotherapy and Oncology , vol.75 , Issue.2 , pp. 141-148
    • Sundstrom, S.1    Bremnes, R.2    Brunsvig, P.3    Aasebo, U.4    Klepp, O.5    Fayers, P.M.6    Kaasa, S.7
  • 41
    • 1542713367 scopus 로고    scopus 로고
    • Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial
    • DOI 10.1200/JCO.2004.06.123
    • Sundstrøm S, Bremnes R, Aasebø U, et al: Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial. J Clin Oncol 22:801-810, 2004 (Pubitemid 41103591)
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.5 , pp. 801-810
    • Sundstrom, S.1    Bremnes, R.2    Aasebo, U.3    Aamdal, S.4    Hatlevoll, R.5    Brunsvig, P.6    Johannessen, D.C.7    Klepp, O.8    Fayers, P.M.9    Kaasa, S.10
  • 44
    • 33644684204 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group
    • Sederholm C, Hillerdal G, Lamberg K, et al: Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 23:8380-8388, 2005
    • (2005) J Clin Oncol , vol.23 , pp. 8380-8388
    • Sederholm, C.1    Hillerdal, G.2    Lamberg, K.3
  • 46
    • 33745632406 scopus 로고    scopus 로고
    • A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/ cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: A randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
    • DOI 10.1093/annonc/mdl078
    • Booton R, Lorigan P, Anderson H, et al: A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: A randomized multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol 17:1111-1119, 2006 (Pubitemid 43985247)
    • (2006) Annals of Oncology , vol.17 , Issue.7 , pp. 1111-1119
    • Booton, R.1    Lorigan, P.2    Anderson, H.3    Baka, S.4    Ashcroft, L.5    Nicolson, M.6    O'Brien, M.7    Dunlop, D.8    O'Byrne, K.9    Laurence, V.10    Snee, M.11    Dark, G.12    Thatcher, N.13
  • 49
    • 33847408454 scopus 로고    scopus 로고
    • Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer
    • Manegold C, Koschel G, Hruska D, et al: Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 8:245-251, 2007 (Pubitemid 46333569)
    • (2007) Clinical Lung Cancer , vol.8 , Issue.4 , pp. 245-251
    • Manegold, C.1    Koschel, G.2    Hruska, D.3    Schott-von-Romer, K.4    Mezger, J.5    Pilz, L.R.6
  • 50
    • 33847276516 scopus 로고    scopus 로고
    • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
    • DOI 10.1093/annonc/mdl377
    • Ohe Y, Ohashi Y, Kubota K, et al: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317-323, 2007 (Pubitemid 46323100)
    • (2007) Annals of Oncology , vol.18 , Issue.2 , pp. 317-323
    • Ohe, Y.1    Ohashi, Y.2    Kubota, K.3    Tamura, T.4    Nakagawa, K.5    Negoro, S.6    Nishiwaki, Y.7    Saijo, N.8    Ariyoshi, Y.9    Fukuoka, M.10
  • 52
    • 55649089263 scopus 로고    scopus 로고
    • Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10
    • Bezjak A, Lee CW, Ding K, et al: Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10. J Clin Oncol 26:5052-5059, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 5052-5059
    • Bezjak, A.1    Lee, C.W.2    Ding, K.3
  • 54
    • 34247106263 scopus 로고    scopus 로고
    • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer Scheduled to Receive First-Line Chemotherapy
    • DOI 10.1097/JTO.0b013e318031cd9a, PII 0124389420070300000008
    • Crawford J, Robert F, Perry MC, et al: A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2:210-220, 2007 (Pubitemid 47181326)
    • (2007) Journal of Thoracic Oncology , vol.2 , Issue.3 , pp. 210-220
    • Crawford, J.1    Robert, F.2    Perry, M.C.3    Belani, C.4    Williams, D.5
  • 55
    • 34247154396 scopus 로고    scopus 로고
    • A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly
    • DOI 10.1097/JTO.0b013e318031d06f, PII 0124389420070300000010
    • Leong SS, Toh CK, Lim WT, et al: A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2:230-236, 2007 (Pubitemid 47181328)
    • (2007) Journal of Thoracic Oncology , vol.2 , Issue.3 , pp. 230-236
    • Leong, S.S.1    Toh, C.K.2    Lim, W.T.3    Lin, X.4    Tan, S.B.5    Poon, D.6    Tay, M.H.7    Foo, K.F.8    Ho, J.9    Tan, E.H.10
  • 61
    • 36849019938 scopus 로고    scopus 로고
    • Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinumbased chemotherapy in non-small-cell lung cancer
    • Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinumbased chemotherapy in non-small-cell lung cancer. J Clin Oncol 25:5233-5239, 2007
    • (2007) J Clin Oncol , vol.25 , pp. 5233-5239
    • Park, J.O.1    Kim, S.W.2    Ahn, J.S.3
  • 62
    • 37549069291 scopus 로고    scopus 로고
    • Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced nonsmall cell lung cancer: A randomized, multicenter phase III trial
    • Georgoulias V, Androulakis N, Kotsakis A, et al: Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced nonsmall cell lung cancer: A randomized, multicenter phase III trial. Lung Cancer 59:57-63, 2008
    • (2008) Lung Cancer , vol.59 , pp. 57-63
    • Georgoulias, V.1    Androulakis, N.2    Kotsakis, A.3
  • 63
    • 39749087795 scopus 로고    scopus 로고
    • Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2
    • DOI 10.1200/JCO.2007.13.2720
    • Lilenbaum R, Axelrod R, Thomas S, et al: Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-smallcell lung cancer and a performance status of 2. J Clin Oncol 26:863-869, 2008 (Pubitemid 351398077)
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.6 , pp. 863-869
    • Lilenbaum, R.1    Axelrod, R.2    Thomas, S.3    Dowlati, A.4    Seigel, L.5    Albert, D.6    Witt, K.7    Botkin, D.8
  • 65
    • 67249163661 scopus 로고    scopus 로고
    • Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: An NCCTG-97-24-51 based study
    • Yang P, Mandrekar SJ, Hillman SH, et al: Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: An NCCTG-97-24-51 based study. J Thorac Oncol 4:479-485, 2009
    • (2009) J Thorac Oncol , vol.4 , pp. 479-485
    • Yang, P.1    Mandrekar, S.J.2    Hillman, S.H.3
  • 66
    • 52049096854 scopus 로고    scopus 로고
    • Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): Randomized, phase II study
    • Crinò L, Cappuzzo F, Zatloukal P, et al: Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): Randomized, phase II study. J Clin Oncol 26:4253-4260, 2008
    • (2008) J Clin Oncol , vol.26 , pp. 4253-4260
    • Crinò, L.1    Cappuzzo, F.2    Zatloukal, P.3
  • 67
    • 51049116840 scopus 로고    scopus 로고
    • Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: A prospective randomized phase III trial of the G.O.C.I.M. (Gruppo Oncologico Italia Meridionale)
    • Gebbia V, Galetta D, Lorusso V, et al: Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: A prospective randomized phase III trial of the G.O.C.I.M. (Gruppo Oncologico Italia Meridionale). Lung Cancer 61:369-377, 2008
    • (2008) Lung Cancer , vol.61 , pp. 369-377
    • Gebbia, V.1    Galetta, D.2    Lorusso, V.3
  • 68
    • 59149092945 scopus 로고    scopus 로고
    • Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer
    • Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 591-598
    • Fidias, P.M.1    Dakhil, S.R.2    Lyss, A.P.3
  • 69
    • 67349140361 scopus 로고    scopus 로고
    • How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group
    • Nyman J, Friesland S, Hallqvist A, et al: How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 65:62-67, 2009
    • (2009) Lung Cancer , vol.65 , pp. 62-67
    • Nyman, J.1    Friesland, S.2    Hallqvist, A.3
  • 70
    • 67650281462 scopus 로고    scopus 로고
    • Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer
    • Grønberg BH, Bremnes RM, Fløtten O, et al: Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217-3224, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 3217-3224
    • Grønberg, B.H.1    Bremnes, R.M.2    Fløtten, O.3
  • 71
    • 69549116226 scopus 로고    scopus 로고
    • Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced nonsmall cell lung cancer: A randomized phase II clinical trial
    • Zwitter M, Kovac V, Smrdel U, et al: Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced nonsmall cell lung cancer: A randomized phase II clinical trial. J Thorac Oncol 4:1148-1155, 2009
    • (2009) J Thorac Oncol , vol.4 , pp. 1148-1155
    • Zwitter, M.1    Kovac, V.2    Smrdel, U.3
  • 72
    • 70449720894 scopus 로고    scopus 로고
    • Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer
    • Lee SM, Rudd R, Woll PJ, et al: Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:5248-5254, 2009
    • (2009) J Clin Oncol , vol.27 , pp. 5248-5254
    • Lee, S.M.1    Rudd, R.2    Woll, P.J.3
  • 73
    • 77649203360 scopus 로고    scopus 로고
    • Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: Results of a west Japan thoracic oncology group trial (WJTOG0203)
    • Takeda K, Hilda T, Sato T, et al: Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: Results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28:753-760, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 753-760
    • Takeda, K.1    Hilda, T.2    Sato, T.3
  • 74
    • 77949891126 scopus 로고    scopus 로고
    • Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099
    • Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
    • (2010) J Clin Oncol , vol.28 , pp. 911-917
    • Lynch, T.J.1    Patel, T.2    Dreisbach, L.3
  • 75
    • 77953539831 scopus 로고    scopus 로고
    • Two schedules of chemotherapy for patients with nonsmall cell lung cancer in poor performance status: A phase II randomized trial
    • Zwitter M, Kovac V, Rajer M, et al: Two schedules of chemotherapy for patients with nonsmall cell lung cancer in poor performance status: A phase II randomized trial. Anticancer Drugs 21:662-668, 2010
    • (2010) Anticancer Drugs , vol.21 , pp. 662-668
    • Zwitter, M.1    Kovac, V.2    Rajer, M.3
  • 77
    • 0028275927 scopus 로고
    • The EORTC QLQ-LC13: A modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials
    • DOI 10.1016/0959-8049(94)90535-5
    • Bergman B, Aaronson NK, Ahmedzai S, et al: The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials-EORTC Study Group on Quality of Life. Eur J Cancer 30A: 635-642, 1994 (Pubitemid 24164250)
    • (1994) European Journal of Cancer Part A: General Topics , vol.30 , Issue.5 , pp. 635-642
    • Bergman, B.1    Aaronson, N.K.2    Ahmedzai, S.3    Kaasa, S.4    Sullivan, M.5
  • 78
    • 0028471807 scopus 로고
    • Quality of life during clinical trials: Conceptual model for the lung cancer symptom score (LCSS)
    • Hollen PJ, Gralla RJ, Kris RG, et al: Quality of life during clinical trials: Conceptual model for the lung cancer symptom score (LCSS). Support Care Cancer 2:213-222, 1994
    • (1994) Support Care Cancer , vol.2 , pp. 213-222
    • Hollen, P.J.1    Gralla, R.J.2    Kris, R.G.3
  • 79
    • 0028267598 scopus 로고
    • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the lung cancer symptom scale
    • Hollen PJ, Gralla RJ, Kris MG, et al: Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73:2087-2098, 1994 (Pubitemid 24107963)
    • (1994) Cancer , vol.73 , Issue.8 , pp. 2087-2098
    • Hollen, P.J.1    Gralla, R.J.2    Kris, M.G.3    Cox, C.4    Belani, C.P.5    Grunberg, S.M.6    Crawford, J.7    Neidhart, J.A.8
  • 81
    • 0025639135 scopus 로고
    • Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam symptom checklist
    • de Haes JCJM, van Knipperberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam symptom checklist. Br J Cancer 62:1034-1038, 1990
    • (1990) Br J Cancer , vol.62 , pp. 1034-1038
    • De Haes, J.C.J.M.1    Van Knipperberg, F.C.E.2    Neijt, J.P.3
  • 82
    • 0033006597 scopus 로고    scopus 로고
    • The rapid assessment of fatigue severity in cancer patients: Use of the brief fatigue inventory
    • DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0. CO;2-N
    • Mendoza TR, Wang XS, Cleeland CS, et al: The rapid assessment of fatigue severity in cancer patients: Use of the Brief Fatigue Inventory. Cancer 85:1186-1196, 1999 (Pubitemid 29115600)
    • (1999) Cancer , vol.85 , Issue.5 , pp. 1186-1196
    • Mendoza, T.R.1    Wang, X.S.2    Cleeland, C.S.3    Morrissey, M.4    Johnson, B.A.5    Wendt, J.K.6    Huber, S.L.7
  • 83
    • 0029952658 scopus 로고    scopus 로고
    • EuroQol: The current state of play
    • DOI 10.1016/0168-8510(96)00822-6
    • Brooks R: EuroQol: The current state of play. Health Policy 37:53-72, 1996 (Pubitemid 26191458)
    • (1996) Health Policy , vol.37 , Issue.1 , pp. 53-72
    • Brooks, R.1    De Charro, F.2
  • 85
    • 0031972496 scopus 로고    scopus 로고
    • Interpreting the significance of changes in health-related quality-of- life scores
    • Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in healthrelated quality-of-life scores. J Clin Oncol 16:139-144, 1998 (Pubitemid 28041591)
    • (1998) Journal of Clinical Oncology , vol.16 , Issue.1 , pp. 139-144
    • Osoba, D.1    Rodrigues, G.2    Myles, J.3    Zee, B.4    Pater, J.5
  • 86
    • 33748805503 scopus 로고    scopus 로고
    • Progress and problems for randomized clinical trials: From streptomycin to the era of megatrials
    • DOI 10.1093/eurheartj/ehl152
    • Hilbrich L, Sleight P: Progress and problems for randomized clinical trials: From streptomycin to the era of megatrials. Eur Heart J 27:2158-2164, 2006 (Pubitemid 44412828)
    • (2006) European Heart Journal , vol.27 , Issue.18 , pp. 2158-2164
    • Hilbrich, L.1    Sleight, P.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.